KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.90 USD
-0.16 (-2.64%)
Updated Aug 28, 2024 01:57 PM ET
After-Market: $5.96 +0.06 (1.02%) 7:42 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 281 - 300 ( 367 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Dry Eye: Top-line STRIDE 3 Data by YE; NDA Resubmission Expected in H1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Complete Response Letter Received as Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Revenue Miss; Reiterate Buy; Reducing PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q2; INVELTYS Sales Growth Steady; Dry Eye PDUFA on August 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department